Evidence map›Paper›PMID 39621785›Full record

ArticlePLoS pathogens2024

SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization.

Enya Qing, Julisa Salgado, Alexandria Wilcox, Tom Gallagher

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Enya QingDepartment of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, United States of America.ORCID 0000-0002-7455-3463
Julisa SalgadoDepartment of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, United States of America.
Alexandria WilcoxMcKelvey School of Engineering, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Tom GallagherDepartment of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, United States of America.ORCID 0000-0002-8601-5961

Funding

Impacts of Adaptive Coronavirus Evolution on Viral Membrane FusionR21AI178391 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI GALLAGHER, THOMAS MILLER · 2023 to 2024
$437k
NIAID NIH HHS R21 AI178391
6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is adapting to continuous presence in humans. Transitions to endemic infection patterns are associated with changes in the spike (S) proteins that direct virus-cell entry. These changes generate antigenic drift and thereby allow virus maintenance in the face of prevalent human antiviral antibodies. These changes also fine tune virus-cell entry dynamics in ways that optimize transmission and infection into human cells. Focusing on the latter aspect, we evaluated the effects of several S protein substitutions on virus-cell membrane fusion, an essential final step in enveloped virus-cell entry. Membrane fusion is executed by integral-membrane "S2" domains, yet we found that substitutions in peripheral "S1" domains altered late-stage fusion dynamics, consistent with S1-S2 heterodimers cooperating throughout cell entry. A specific H655Y change in S1 stabilized a fusion-intermediate S protein conformation and thereby delayed membrane fusion. The H655Y change also sensitized viruses to neutralization by S2-targeting fusion-inhibitory peptides and stem-helix antibodies. The antibodies did not interfere with early fusion-activating steps; rather they targeted the latest stages of S2-directed membrane fusion in a novel neutralization mechanism. These findings demonstrate that single amino acid substitutions in the S proteins both reset viral entry-fusion kinetics and increase sensitivity to antibody neutralization. The results exemplify how selective forces driving SARS-CoV-2 fitness and antibody evasion operate together to shape SARS-CoV-2 evolution.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusVirus InternalizationAnimalsHumansMembrane FusionAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39621785
PMCPMC11637440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.